

Oncodesign
Precision Medicine

Presentation

April 2023

ELIGIBLE PEA PME

Warning

OPM makes no representations or warranties about, or based on, any statistical information or forward-looking information contained in this presentation that is derived from third-party sources or industry publications; such statistical data and forward-looking information are used in this presentation for informational purposes only.

This presentation contains only summarized information and should not be considered exhaustive. The objectives, statements and forward-looking information of OPM contained in this document are provided for illustrative purposes only and are based on current assessments and assumptions of management. These objectives, statements and forward-looking information, including express or implied statements regarding future sales and revenues, involve known and unknown risks and uncertainties that may cause the Group's results, achievements or performance to be materially different from those anticipated in the summarized information. A number of factors could cause actual results and developments to differ materially from those expressed or implied in the forward-looking information. OPM disclaims any obligation or undertaking to update or revise any of the targets, statements and information contained in this presentation as a result of changes in OPM's strategy or intentions or in the course of events or in the conditions, assumptions or circumstances on which any such information was based, except as required by law.

This document does not constitute an offer to sell or a solicitation to invest in securities in any country. In France, the offer of securities of OPM may only be made by means of a prospectus or under an exemption from the obligation to publish a prospectus and outside France, only by means of a translation of this prospectus prepared for this purpose and only in countries and under circumstances where such offerings comply with the applicable regulations. No offering in or outside of France is contemplated. OPM's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act.

An experienced team of 3 managers working together for 14 years



Philippe Genne
Chairman and CEO
PhD in Pharmacology

- Creation of Oncodesign Biotechnology in 1995: Founder, CEO and CSO
- IPO Oncodesign Biotechnology in 2014
- Creation of the AFSSI
- Vice President SME and ETI Medicen

Jan Hoflack
Chief Scientific Officer
PhD in Organic Chemistry

- Creator of the Nanocyclix® technology
- Executive at Marion Merrell Dow, Novartis and AstraZeneca
- Vice President, Medicinal Chemistry and Biosciences at Johnson & Johnson
- Joined Oncodesign Biotechnology in 2009: CSO

Karine Lignel
Chief Operating Officer
Engineer and
Master in Finance and Management

- supported more than 60 technology companies, mainly in the health sector (IPO Nanobiotix, Oncodesign Biotechnology and Medincell)
- Has been a member of more than 30 boards of directors or supervisory boards, including Oncodesign Biotechnology from 2008 to 2021
- Joined Oncodesign Biotechnology in 2021: CBO

A team that sold Oncodesign Services (100 M€)
And led the IPO of Oncodesign Precision Medicine in 2022 on Euronext Growth Paris

Identity card

IPO in September **2022**

Euronext Growth Paris

Dijon

Head office

25 international employees

including **11 PhDs**

Co-founders:

- Philippe Genne
- Jan Hoflack
- Karine Lineel

Financing history

- **7 M€ in October 2022**
  LRRK2 (license option) SERVIER moved by you
- **0.5 M€ in November 2022**
  Start Pancreas (upfront) SERVIER moved by you
- Capital increase in December 2022 :
  8 M€, of which 5 M€ subscribed by the management

Our strengths

A successful entrepreneurial path

An experienced and committed team: in-depth knowledge of the pharma, biotech and financial ecosystems and a very strong experience in preclinical R&D

Molecules derived from our technologies already in the clinic addressing huge markets: Parkinson's disease (1% of the population over 60) and Chronic Inflammatory Bowel Diseases (CIBD) with a potential for us of 1 billion € in 2030 (20/30% of reference treatments)

A real partnership culture (Servier, SEngine, Ipsen, BMS, Sanofi, UCB…)

A strong strategic partnership with the CRO Oncodesign Services to control and accelerate preclinical development

OUR MISSION

Discover and develop new innovative therapies effective against advanced and resistant cancers

HOW?

Through precision medicine addressed against therapeutic resistance and metastatic development

OPM: a clinical stage biopharmaceutical « pure player »

Three innovative and proprietary technology platforms

Target identification → Target validation → Lead identification → Lead optimization → Preclinical → Clinic

Resistant and metastatic patients
ONCOSNIPER

Identify and validate new therapeutic targets to fight against treatment resistance in oncology: understanding the biological mechanisms

Kinase inhibitors
NANOCYCLIX®

SEngine Precision Medicine

Identify effective, highly specific kinase inhibitors targeted interaction with biological mechanisms

- ODS-101
- ODS-5981 — SERVIER moved by you

Drug discovery using AI

Radioconjugate vector
PROMETHE

- MRT-1

Developing Vectorized Internal Radiation Therapy (VIR/MRT) for therapeutic use: bringing radiation therapy to tumor cells

A virtuous model for *Drug Discovery*



Artificial Intelligence at the heart of our model, making the *Drug Discovery* process more reliable and faster

A strong partnership culture

- **Current Partnerships:**

  - Partnership on the research of a drug candidate since 2019
  - Partnering on AI-based target search since 2022

  - Partnership on the search for new targets in oncology since 2022

- **Past partnerships :**

- **Strong capacity to create/integrate in consortia: PharmImage, OncoSNIPE**

A pipeline of differentiated clinical and preclinical programs



Indication		Next step
LRRK2 ODS'5981	Parkinson's disease SERVIER	Results Phase 1: Q2 2024
RIPK2 ODS'101	Chronic Inflammatory Bowel Diseases	Intermediate results Phase 1: end of 2023
STarT Pancreas	Pancreatic cancer SERVIER	Identification of the 1ère target: before the end of 2023
EGFR Florepizole	Radiotracer Oncology	Search for a partner to start Phase 3 directly
Validation of candidates	Oncology SEngine Precision Medicine	New target validated *in vivo* from patient organoids
RIPK2	Oncology	Validation of the value of RIPK2 against aggressive tumors and identification of IND: mid-2024
MRT 1 HER2	Oncology	Vector technology partnership and progression Phase 1: 2025
MRT 2	Oncology	Construction of a pipeline of MRTs: 2023/2024
MRT 3	Oncology	Construction of a pipeline of MRTs: 2023/2024



Our Precision Medicine platform based on innovative technologies

OncoSNIPER

Identify and validate new therapeutic targets to overcome treatment resistance in oncology

Resistant and metastatic patients
ONCOSNIPER

Target identification → **Target validation** → Lead identification → Lead optimization → Preclinical → Clinic

Public, private and **especially proprietary data sources** from projects such as IMODI and OncoSNIPE®

AI Technologies: Machine Learning & Deep Learning

Drug Discovery **Expert Knowledge**

Contribution of Oncodesign Services experimental platforms

Choice of intra and extra cellular therapeutic target families: Kinases/ surface proteins

OncoSNIPER

To develop partnerships for the discovery of new targets and biomarkers

To enter into licensing agreements with pharmaceutical and biotech companies for previously identified therapeutic targets

OncoSNIPER applications: StarT Pancreas and in the proprietary medicinal chemistry platform, Nanocyclix

Oncodesign Services is our prefered subcontracting partner

Nanocyclix

proprietary medicinal chemistry technology

Kinase inhibitors
NANOCYCLIX®

Target identification → Target validation → **Lead identification** → **Lead optimization** → Preclinical → Clinic

Proprietary platform
Complete platform of macrocyclic kinase inhibitors without equivalent in the industry

A large library of kinase inhibitors
11,000+ macrocycles, 50+ scaffolds and 300+ distinct linkers

Favorable properties
These kinase inhibitors are potent, highly selective, and have good cellular penetration



Two molecules in the clinic: ODS-101 on RIPK2 and ODS-5981 on LRRK2
Several leads identified, both for known kinases and those discovered by OPM: they could become tomorrow's targeted therapies in precision medicine

PROMETHE
PRecision Oncology MEdicine ThEranostics

Radioconjugate vector
PROMETHE

Emergence of a revolutionary Vectorized Internal Radiation Therapy (VIRT) technology for therapeutic use



Molecules targeting proteins expressed on cancer cells

High selectivity, starting from vectors that can be small molecules, peptides, or different forms of antibodies depending on the chosen target.

To these vectors are coupled a linker and a chelating cage by bio-conjugation

The latter allows the capture of radioisotopes, which, depending on the type of radionuclide used, make them imaging or therapeutic agents



PET images after injection of ^{68} Ga-PSMA

This theranostic approach capitalizes on the proprietary platform of a recognized partner with whom we are in discussion to jointly develop several MRTs through a Joint Venture

Sources: Theranostic in oncology with PSMA // 177 Lu-PSMA radioligand therapy in a 67-year-old man with metastatic castration-resistant prostate cancer. A: PET image evidenced a difuse metastatic involvement. PSA value 50 ng/ml. B: 4 months following the treatment with 177 Lu-PSMA radioligand therapy (8000 MBq), PET showed a complete metabolic response. PSA value 0 ng/ml

Our clinical development programs

RIPK2

a kinase of the innate immune system, targeted to treat IBD

RIPK2 is part of a complex activated by bacterial infections, with the purpose of killing infected cells to protect the body.

The pathological hyperactivity of this complex gives rise to inflammatory diseases, especially in the colon.

20 to 30%
of current reference treatment sales (ENTYVIO sales and its successors) estimated in 2030

> 1 billion US$
Blockbuster potential

About Inflammatory Bowel Disease (IBD)

IBD is one of the autoimmune and inflammatory pathologies, linked to a deregulation of the immune system

First indications in IBD for RIPK2:
- Crohn's disease and ulcerative colitis

Potential to represent a "franchise" target
- Other inflammatory and autoimmune diseases
- Aggressive and metastatic cancers

The clinical proof of concept of ODS-101 in IBD is conducted by OPM prior to the sale of a license to a major pharma company or companies

ODS-101

The leading proprietary program from the Nanocyclix® platform to inhibit RIPK2

Kinase inhibitors
NANOCYCLIX®

A Best-in-Class inhibitor of the RIPK2 target in IBD

- Best-in-Class molecule for RIPK2 target **in Phase 1 healthy volunteers**
- First compound of series allowing to derisk the program and to position it in multiple indications

➔ **Potential additional positioning on immunotherapy-induced colitis in oncology**



ODS-101 phase I healthy volunteers



Endpoints
1º Safety, MTD
2º PK, Dose Selection
Explo. Biomarkers: POC

Single administration dose

- The cohorts are composed of 8 male volunteers including 2 sentinels followed by 3+3, 4+2 or 2+4
- **First cohort - 5 mg** (completed March 3), 16 volunteers assessed, 8 included. Decision to proceed to cohort 2.
- **Second cohort - 20 mg** (completed March 24), 2nd volunteers evaluated, 8 included. Decision to proceed to cohort 3.
- **Third cohort - 60 mg** (started March 27)

LRRK2

A kinase with a potential for Parkinson's disease

- **A mutation in the LRRK2 target** was identified in Parkinson's disease patients in 2004
- **A significant increase in LRRK2 kinase activity** is observed in vulnerable dopaminergic neurons of Parkinson's patients, suggesting LRRK2 involvement in most Parkinson's disease patients
- **Biogen/Denali have initiated a Phase 3 trial** with their LRRK2 inhibitor BIIB122. Denali's license to Biogen represented an upfront value of more than US$1 billion.
- Use as a neuroprotective agent and preventive treatment may address **nearly 3 million patients in the 7 MM**

About Parkinson's disease

Progressive neurodegenerative disease affecting **~1%** of the population over 60 years old

Only symptomatic treatments to date

+8.5 million people with Parkinson's disease worldwide in 2019

OPM's LRRK2 program, a potential Best in Class molecule licensed to Servier in 2022 and in Phase 1 healthy volunteers currently, represents a significant potential source of revenue for the Company

ODS'598

a clinical program in partnership with SERVIER, to inhibit LRRK2

Kinase inhibitors
NANOCYCLIX®

A potential Best-in-Class LRRK2 inhibitor, a target with the potential to change the course of Parkinson's disease

310 M€ potential milestones of which **13 M€** already received, in addition to R&D funding (7 M€)

2011: Start of the program
with Ipsen (25 M€ investment)

2017: Ipsen gives the program back
to Oncodesign

2018 : Continuation of the program by Oncodesign

2019

New partnership with Servier

upfront and potential milestones of 310 M€, excluding royalties

2021

Selection of a preclinical candidate

ODS'5981

2022

Regulatory Approval

CTA by the ANSM and the CPP of the phase 1 program

Exercise of the license option

exclusive worldwide agreement by Servier and 7 M€ milestone payment to OPM

Entering the clinic

Phase 1 in healthy volunteers (October 2022)

2023

2024

S1 2024

Final results Phase 1 healthy volunteers

S2 2024

Launch Phase 1b (potential milestone)

Pancreatic cancer

A cancer with no effective therapeutic solution

- **One of the most difficult cancers to treat effectively and inherently resistant**
- **Cancer usually diagnosed in advanced stages** when abdominal pain or jaundice appear: no effective screening tools: **95% of patients** die
- **Pancreatic cancer remains the deadliest and fastest killing cancer**: 1 in 4 patients die within a month, and 3 in 4 within a year.

About the pancreatic cancer

2018 in France:

- **9th** most common **cancer** in men
- **7th cancer** in women
- **14,184 new cases** in France per year

2023 (estimates) in the United States :

- **33,130** men
- **30,920** women
- **50,550** deaths

The genomic revolution represents one of the best hopes for future treatments of pancreatic cancer

Sources: Pancreatic Cancers: Key Points - Pancreatic Cancer (e-cancer.fr); American Cancer Society

STarT Pancreas

A new strategic collaboration with SERVIER

Resistant and metastatic patients
ONCOSNIPER

Identification and validation of therapeutic targets in the treatment of pancreatic cancer

0.5 M€ milestone payment already received



New partnership with Servier

Program from the OncoSNIPE® Pancreas arm and its clinical trial

Start of the OncoSNIPE® program

Stratification and characterization of cancer treatment resistant patient populations

Collection of clinical, biological, genetic and imaging data and samples from chemo-naive patients with :
- Triple negative breast cancer,
- Pancreatic cancer
- Lung cancer

Milestone Payment

0.5 M€ second milestone payment subject to the achievement of certain objectives
(before the end of 2024)

Next steps

- Target identification
- Experimental validation of artificial intelligence findings
- Other milestone payments until validation of the drug candidate(s) entry into Phase 1

Vectorized Internal Radiation Therapy (VIR/MRT)

The ultimate tool for precision medicine

Ongoing joint venture discussions with an identified partner with the mission to :

- Discover innovative and differentiating therapies, effective against advanced, metastatic and resistant cancers and develop them to the clinical stage
- Development of radiotherapeutics for precision medicine



- VIR/MRT is a kind of "radioactive chemotherapy", which aims at destroying cancer cells wherever they are in the body, by specific and targeted cellular mechanisms

KEY STEPS

Development platform for a MRT portfolio with the development of 5 theranostic products (MRT 1 to 5)

VIR/MRT brings radiation therapy to the cellular level of tumors

Strategy and perspectives

Our clinical and preclinical development perspectives



Key financial elements

15,5 M€

cash as of December 5, 2022 of which

- Initial payment Servier (Start Pancreas): 0.5 M€
- Milestone option exercise Servier (LRRK2): 7 M€
- Fundraising December 2022: 8 M€.

Potential Milestones SERVIER

within the framework of our partnerships

- 310 M€ (LRRK2)
- 0.5 M€ (Start Pancreas) by the end of 2024 + other milestone payments until validation of Phase 1 entry

Numerous investments already made, notably in R&D

RIPK2	**22.1 M€** since 2012
LRRK2	**8.9 M€*** since 2011
Platforms	**3.7 M€*** since 2017

* *Excluding expenses incurred directly by the partners of a significant amount (IPSEN then Servier)*

Share price evolution since the IPO October 5, 2022



Share capital post december 22 capital increase December 31, 2022



A capital increase of 8 M€, 5 M€ of which was subscribed by the co-founders

Our strengths

A successful entrepreneurial path

An experienced and committed team: in-depth knowledge of the pharma, biotech and financial ecosystems and a very strong experience in preclinical R&D

Molecules derived from our technologies already in the clinic addressing huge markets: Parkinson's disease (1% of the population over 60) and Chronic Inflammatory Bowel Diseases (CIBD) with a potential for us of 1 billion € in 2030 (20/30% of reference treatments)

A real partnership culture (Servier, SEngine, Ipsen, BMS, GSK, Sanofi, UCB....)

A strong strategic partnership with the CRO Oncodesign Services to control and accelerate preclinical development

Appendices

OPM Governance

A highly experienced team

Executive management



Philippe Genne
Chief Executive Officer
Founder Oncodesign SA

Jan Hoflack
Chief Scientific Officer
Inventor Nanocyclix®
Platform



Karine Lineel
Chief Operating Officer

Management committee

Thierry Billoué
Chief Human Resources
Officer

Arnaud Lafforgue
Chief Financial &
Administrative Officer

Stéphane Gérart
Head of Artificial
Intelligence, Chief
Information Officer



Sylvie Fernandes Forster
Chief Legal Officer

RIPK2



RIPK2 (identified since 2012)
Direct signaling partner of NOD1 and NOD2,
"Pattern recognition receptors" that protect against bacterial infections, and whose deregulation is linked to several IBDs

Our strong intellectual protection

Precise and multi-level intellectual protection: in line with the usual strategies of pharmas and based on our proprietary innovation platforms

Early submission of patents: a clear strategy and efficient management of our patent portfolio

Current **patent portfolio** on Nanocyclix® programs:

- **RIPK2**
- **LRRK2** (co-owned by Servier and OPM) and ;
- **the PET tracer Florepizol**

When filing patents, the initial search reports issued by **patent offices are very favorable**, indicating the uniqueness of our technologies

Currently, there are **5 active patents** protecting our programs

Patent	Application number	Target	Date of registration	Expiry date	Publication date	Status
ONC-026	WO2016042087	RIPK2 Rig.	17/09/2014	17/09/2034	24/03/2016	National phase
ONC-027	WO2017148925	PET Tracer	29/02/2016	29/02/2036	08/09/2017	National phase
ONC-036	WO2021152165	RIPK2 ONN Lactams	31/01/2020	31/01/2040(1)	05/08/2021	National phase
ODS1(2)	WO2021224320	LRRK2 Carbamates	06/05/2020	06/05/2040(1)	11/11/2021	National phase
ODS2(2)	WO2022194976	LRRK2 Ethers/Amides/Amines	18/03/2021	18/03/2041(1)	22/09/2022	Published

(1) As of their approval date (country by country) which is still pending (2) Servier/ODS co-application

Oncodesign
Precision Medicine

Contact us

Oncodesign
Precision Medicine

18 rue Jean Mazen
21000 Dijon France

+33 (0)3 80 78 41 93

oncodesign.com